晚期胃癌小分子靶向治疗的研究进展

Progress in small-molecule tyrosine kinase inhibitors for the treatment of advanced gastric cancer

胃癌是一种起源于胃黏膜上皮的恶性肿瘤,我国胃癌死亡人数占癌症死亡人数的23. 2%。早期胃癌检出率低,常见胃癌多为晚期。化疗是晚期胃癌的主要治疗方法,但化疗药物不良反应严重、耐药率高。目前,作用于特定靶点的小分子靶向药物因其药物不良反应较轻、耐药率低、患者服用方便等优点成为治疗晚期胃癌的新治疗手段之一。治疗晚期胃癌的小分子靶向药物依据作用机制分为抑制肿瘤血管增生和抑制肿瘤细胞增殖两类。本文系统综述了近几年治疗晚期胃癌的小分子靶向药物的研究进展。

In China, the mortality of gastric cancer, a neoplasms origina- ting in the epithelium of gastric mucosa, accounted for 23.2% of cancer. Patients diagnosed as advanced gastric cancer are mostly at advanced stage due to its diagnosis in early stage is difficult. Although chemothera- py is one of the main therapies for advanced gastric cancer, it has disad- vantage of serious adverse reactions and high resistance. At present, the small - molecule inhibitors of target therapy has emerged as a new treat- ment method for advanced gastric cancer, because its advantage of well - tolerant, less adverse reaction and more convenient to use. In the treat- ment of advanced gastric cancer, the small -molecule inhibitors of target therapy can be divided into two categories： inhibiting tumor angiogenesis and inhibiting tumor cell proliferation. In this paper, we reviewed the progress in small - molecule inhibitors of targeted therapy for advanced gastric cancer.